Biomarkers predict outcomes in patients with atrial fibrillation and cardiovascular conditions

Brady, Paul (2022). Biomarkers predict outcomes in patients with atrial fibrillation and cardiovascular conditions. University of Birmingham. M.D.

Preview

Brady2022MD_Redacted.pdf
Text - Redacted Version
Available under License All rights reserved.
Download (2MB) | Preview

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia with a prevalence of 3-4%. Thirteen cardiovascular biomarkers selected in a Delphi process were centrally quantified on high-precision, high-throughput analysers (Roche Diagnostics, Penzberg, Germany) in 1620 patients recruited into Birmingham Black Country Atrial Fibrillation Registry at Sandwell and West Birmingham NHS Trust. Follow-up information on outcomes (cardiovascular death, heart failure hospitalization, stroke or systemic embolism and acute coronary syndrome) were obtained using health records and central mortality data from NHS digital. Follow-up was for a median of 4.2 (IQR 3.5–4.9) years with analysis performed at 2.5 years. Clinical characteristics and biomarker concentrations were related to outcomes. Study 1 examines the value of NT-proBNP in predicting cardiovascular death or heart failure hospitalization in phenotype groups based on AF and heart failure status. Study 2 examines biomarker predictors and clinical predictors of major adverse cardiovascular events (MACE) in patients with cardiovascular conditions.

Type of Work:

Thesis (Higher Doctorates > M.D.)

Award Type:

Higher Doctorates > M.D.

Supervisor(s):